Tandem Diabetes (TNDM) CFO receives 62,657 restricted stock unit award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vosseller Leigh reported acquisition or exercise transactions in this Form 4 filing.

Tandem Diabetes Care executive vice president and chief financial officer Leigh Vosseller received a grant of 62,657 restricted stock units (RSUs) under the company’s 2023 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock or cash at the company’s discretion.

One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms and continued eligibility. This is a stock-based compensation award, not an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vosseller Leigh

Role EVP & CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	62,657	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 62,657 shares (Direct, null)

Footnotes (1)

Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan.

Key Figures

RSUs granted: 62,657 RSUs Total RSUs after grant: 62,657 RSUs Vesting start date: May 29, 2027 +1 more

4 metrics

RSUs granted 62,657 RSUs Award to EVP & CFO Leigh Vosseller

Total RSUs after grant 62,657 RSUs Total derivative holdings reported following transaction

Vesting start date May 29, 2027 One-third of RSUs vest on this date

Quarterly vesting tranches 8 installments Remaining RSUs vest in eight equal quarterly installments

Key Terms

Restricted Stock Unit, 2023 Long-Term Incentive Plan, contingent right, vest

4 terms

Restricted Stock Unit financial

"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2023 Long-Term Incentive Plan financial

"in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan..."

contingent right financial

"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."

vest financial

"One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 04:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vosseller Leigh

(Last)

(First)

(Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	05/29/2026		A		62,657		⁽²⁾	⁽²⁾	Common Stock	62,657	$0	62,657	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

2. One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan.

Remarks:

Ex. 24: Power of Attorney

	/s/ Jerilyn Laskie, Attorney-in-Fact for Leigh A. Vosseller	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Tandem Diabetes Care (TNDM) CFO Leigh Vosseller report on this Form 4?

Leigh Vosseller reported a grant of 62,657 restricted stock units. These RSUs are compensation, not a market trade, and may settle in shares or cash based on Tandem Diabetes Care’s 2023 Long-Term Incentive Plan.

How many restricted stock units were granted to the TNDM CFO?

The CFO received 62,657 restricted stock units. Each RSU is a contingent right to one share of common stock or cash, awarded at a zero exercise price under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan.

What is the vesting schedule for the 62,657 RSUs granted by Tandem Diabetes Care?

One-third of the RSUs vest on May 29, 2027. The remaining balance vests in eight equal quarterly installments on the 15th of the month thereafter, subject to the 2023 Long-Term Incentive Plan terms.

Are the RSUs granted to the TNDM CFO settled in shares or cash?

Each RSU may settle in either one share of Tandem Diabetes Care common stock or cash. The choice between stock and cash is at the company’s discretion under the 2023 Long-Term Incentive Plan and related agreements.

Is this Tandem Diabetes Care Form 4 a stock purchase or sale by the CFO?

No, this Form 4 reports a compensation award, not a market trade. The CFO acquired 62,657 RSUs through a grant, with no open-market buying or selling of Tandem Diabetes Care common shares disclosed.